Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics

Drug Profile

Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics

Alternative Names: CDX-301; Flt-3 ligand; Flt3-L; Mobista; rhuFlt3L

Latest Information Update: 15 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Albert Einstein College of Medicine; Amgen; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai
  • Class Adjuvants; Antineoplastics; Cytokines; Recombinant proteins
  • Mechanism of Action Fms-like tyrosine kinase 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II B cell lymphoma
  • Phase I Solid tumours
  • Discontinued Autoimmune disorders; Infections; Malignant melanoma; Non-Hodgkin's lymphoma; Stem cell mobilisation

Most Recent Events

  • 30 Sep 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA (Parenteral) (NCT03329950)
  • 08 Aug 2018 Celldex plans to initiate enrolment to the combination cohort in a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in September 2018 (NCT03329950)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top